A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT06228326
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lung Cancer, Non-small Cell
- Lung Cancer Metastatic
- Solid Tumor, Adult
- Advanced Cancer
- Lung Cancer (NSCLC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Krystal Biotech, Inc.
- Last updated on ClinicalTrials.gov
- October 24, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- XCancer Research Network/Dothan Hematology & Oncology · Dothan, AL
Arizona · 1
- HonorHealth Research Institute · Scottsdale, AZ
California · 2
- Precision NextGen Oncology · Beverly Hills, CA
- Emad Ibrahim MD Inc · Redlands, CA
Florida · 1
- BRCR Global · Weston, FL
Louisiana · 1
- Ochsner/MD Anderson Cancer Center · New Orleans, LA
Michigan · 1
- Henry Ford Health · Detroit, MI
Ohio · 2
- Gabrail Cancer Center Research · Canton, OH
- Cleveland Clinic · Cleveland, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.